ABC of wound healing:Infections
Despite optimal treatment
some wounds are slow to heal. The challenge clinically and
microbiologically is to identify those wounds in which healing is impaired
as a result of infection or heavy bacterial burden and in which systemic or
topical antimicrobial treatment will be of benefit.
Staphylococci and streptococci are the most commonly
encountered pathogenic organisms in community acquired superficial wounds.
More unusual organisms may be found in bite wounds, and these reflect the
source of the bite. Pathogenic organisms causing surgical wound infections
vary according to the anatomical site of surgery. Antibiotic resistant
organisms, such as methicillin resistant Staphylococcus
aureus (MRSA), are more commonly
encountered, reflecting the hospital flora.
When to sample
It is inappropriate to swab all wounds: swabs should be
taken only from overtly infected wounds and from wounds that are
deteriorating, increasing in size, or failing to make satisfactory progress
despite an optimal environment for wound healing. Indicators of wound
infection include redness, swelling, purulent exudate, smell, pain, and
systemic illness in the absence of other foci. Subtle signs of local wound
infection include unhealthy "foamy" granulation tissue, contact
bleeding, tissue breakdown, and epithelial bridging.
Types of sample
Superficial wound swabs-The
ease of obtaining and processing superficial wound swabs, combined with
their relatively low cost and non-invasive nature, make them in most
instances the most appropriate method for wound sampling. Organisms
cultured from a superficial swab may, however, simply reflect the
colonising bacterial flora and are not always representative of the
pathogenic organisms invading deeper tissue. This is particularly relevant
to deep surgical and deep penetrating wounds in which infection from
internal sources may occur.
Tissue and pus-Tissue
or pus, or both, should be collected whenever possible, as growth from
these samples is more representative of pathogenic flora. These are
amenable to quantitative microbiological analysis and other techniques used
to improve the diagnostic yield. Tissue biopsy should always be carried out
when therapeutic debridement of the wound is done, in cases of
osteomyelitis, and when superficial sampling methods have been ineffective.
Less invasive techniques-Less
invasive sampling techniques-such as dermabrasion and various
absorbent pads-have been developed. A wide range of products is
available, but no single method is used routinely yet.
How to take a superficial wound swab
- Removal of
superficial debris followed by swabbing of the wound bed is considered to
be the best way to obtain a superficial wound swab
- Swabs
containing transport media and charcoal should be used as they help to
preserve bacteria before laboratory analysis
- Timely delivery of the swab to the
microbiology laboratory is essential
Microbiological analysis
Semiquantitative analysis
Most laboratories will perform a semiquantitative
analysis on wound swabs. This entails grading bacterial growth as scanty,
light, moderate, or heavy. Semiquantitative analysis introduces a bias
towards motile and fast growing organisms.Infection is a major source of
failed wound healing
Fastidious organisms such as anaerobes may be
under-represented. Semiquantitative counts have been shown to correlate
with quantitative tissue counts in both burn wounds and diabetic foot
ulcers.
Quantitative analysis
Bacterial load greater than 100 000 organisms or colony
forming units per gram of tissue or mm3 of pus is a predictor of wound
infection.
However, some wounds that are more heavily colonised
will heal spontaneously, and, conversely, some organisms are able to cause
serious infection at much lower levels of colonisation. Infection depends
on the pathogenicity of the organism, the type of wound, and the host
response.
Interpretation of results
Most wound swabs will yield bacterial growth. Growth of
bacteria from wounds is not synonymous with infection, and treatment based
on microbiological results alone is not warranted.
Treatment
Wound infections in association with systemic illness,
deep invasion, or cellulitis require empirical systemic antibiotic
treatment while culture results are awaited. Choice of treatment will
depend on factors such as the type and site of wound; previous
microbiological results; and host factors such as drug allergies.
Clinicians must always be alert to the possibility of necrotising
fasciitis. A high level of suspicion followed by prompt aggressive surgical
debridement of devitalised necrotic tissue is essential if the patient is
to survive. Important clinical markers include pain disproportionate to
clinical signs, anaesthesia over the infected area, and systemic illness.
Treatment of locally infected wounds with topical
antiseptics such as silver compounds or iodine will be sufficient in most
instances. Topical treatment avoids the potential side effects of systemic
antibiotics, such as Clostridium difficile diarrhoea, anaphylaxis, gastrointestinal upset, and,
perhaps most importantly, selection of resistant organisms. Systemic
treatment may be indicated if topical medication is unsuccessful.
In general, topical antibiotics are not recommended.
Reasons for this include inadequate penetration for deep skin infections,
development of antibiotic resistance, hypersensitivity reactions, systemic
absorption when applied to large wounds, and local irritant effects leading
to further delay in wound healing. Short courses of silver sulfadiazine or
topical metronidazole can be useful, however, in certain
circumstances-for example, with burns and chronic ulcers.
Topical antimicrobial preparations
- Iodine releasing agents
(povidone-iodine preparations, cadexomer-iodine preparations)
- Potassium
permanganate solution
- Silver
releasing agents (composite silver dressings, silver sulfadiazine)
- Topical antibiotic
(metronidazole)
Osteomyelitis associated with wound infection
Osteomyelitis may develop after direct inoculation of
bone from a contiguous focus of infection. This can be a devastating
complication of wound infection, requiring specialist intervention and
management.
Diagnosis
The diagnosis of osteomyelitis should be considered in
any chronic wound that does not heal despite optimal treatment or in any
wound (especially in those with diabetes) that can be probed to bone. Plain
x rays of the affected area should be the first line of investigation.
Radiographic changes, however, can lag behind the
evolution of infection by at least two weeks; a single, negative plain x
ray film does not, therefore, exclude osteomyelitis. Magnetic resonance
imaging is more sensitive than plain radiography. Nuclear
scintigraphy-either a technetium bone scan or a labelled white cell
scan-may also be helpful but requires careful interpretation. It can
be difficult to differentiate osteomyelitis from chronic soft tissue
infection.
Management
Antibiotics penetrate poorly into devitalised bone, and
long courses of antibiotics may be required. It is therefore important to
define the infecting organism(s) from the outset so that antibiotic
treatment can be targeted. Ideally, in the absence of systemic illness,
antibiotics should not be started before microbiological sampling of the
infected bone.
Surgery followed by prolonged intravenous antibiotic
treatment (generally a minimum of six weeks), is indicated in selected
patients. Periodic antibiotic treatment at times of wound deterioration or
of systemic illness may be appropriate if cure is unachievable.
Surgery
Surgery enables debridement of all necrotic bone and
tissue and provides deep samples for microbiological analysis. In some
patients, surgery is not possible either because of the site of the wound
or because of the patient's debility. Under these circumstances, a
prolonged course of antibiotics may be warranted.
Antibiotic treatment
Choice of treatment is dependent on the antibiotic
sensitivity pattern of the infecting organism(s) along with antibiotic
properties, such as bone penetration, and host factors, such as drug
allergy. Combination therapy is often used to gain maximal effect.
Inflammatory markers (including C reactive protein and erythrocyte
sedimentation rate) and radiological images can be used to monitor
response.
A charcoal swab preserves bacteria during transport to
the laboratory
Punch biopsy for microbiological analysis
Semiquantitative analysis of swab showing light or
scanty, moderate, and heavy growth of Staphylococcus aureus
Methicillin resistant Staphylococcus
aureus
The incidence of MRSA wound infection and osteomyelitis
is increasing. Isolation of MRSA from a wound, however, does not require
treatment in the absence of clinical signs of infection. Topical
antimicrobial agents, such as iodine and silver compounds, have activity
against MRSA and may be used in localised wound infection when there is no
evidence of invasion, cellulitis, or systemic upset.
In a systemically unwell individual, a glycopeptides
(vancomycin or teicoplanin) should be administered. In all cases of MRSA
osteomyelitis and in some MRSA wound infections a second antistaphylococcal
agent with good penetration to bone and superficial skin sites should be
added-for example, fusidic acid or rifampicin. Both rifampicin and
fusidic acid can cause hepatitis and require regular monitoring of liver
function tests.
With the exception of linezolid, evidence for the use
of oral antibiotics in MRSA infections is lacking. However, when oral
antibiotics are used, combinations are recommended to protect against the
development of resistance. Combinations of rifampicin or fusidic acid with
either trimethoprim or minocycline have been used with some success. The
combination of rifampicin with fusidic acid is not advisable because of the
increased risk of hepatotoxicity.
Linezolid, an oxazolidinone, is a new agent active
against MRSA. It has excellent bioavailability, can be administered orally,
and has good skin and bone penetration. Linezolid is generally well
tolerated, but can cause bone marrow suppression, and regular
haematological monitoring is therefore required. Linezolid use is currently
limited by its high cost.
Agents that may be available in the near future include
daptomycin, tigecycline, and dalbavancin.
Further Reading
- Hasham S, Matteucci P, Stanley PR, Hart NB. Necrotising fasciitis. BMJ 2005;330:830-3
- Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C, Linezolid CSSTI Study
Group. Linezolid versus vancomycin in treatment of complicated skin and
soft tissue infections. Antimicrob Agents
Chemother 2005;49:2260-6
- Eron LJ, Lipsky
BA, Low DE, Nathwani D, Tice AD, Volturo GA, Expert Panel on Managing Skin
and Soft Tissue Infections. Managing skin and soft tissue infections:
expert panel recommendations on key decision points. J Antimicrob Chemother 2003;52(suppl
1):i3-17
- Bisno AL, Cockerill FR 3rd, Bermudez CT. The
initial outpatient-physician encounter in group A streptococcal necrotizing
fasciitis. Clin Infect Dis 2000;31:607-8.
Brendan Healy, specialist
registrar in infection diseases and microbiology
Andrew Freedman , honorary consultant
in infectious diseases, University Hospital
of Wales, Cardiff
Competing interests:
KGH's unit receives income from many commercial companies for
research and education, and for advice. It does not support one
company's products over another.The figure showing the spectrum of
interaction between bacteria and host was supplied by J E Grey and Stuart
Enoch.
The ABC of wound healing is edited by Joseph E Grey
(joseph.grey@cardiffandvale.wales.nhs.uk), consultant physician, University
Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, and honorary
consultant in wound healing at the Wound Healing Research Unit, Cardiff
University, and by Keith G Harding, director of the Wound Healing Research
Unit, Cardiff University, and professor of rehabilitation medicine (wound
healing) at Cardiff and Vale NHS Trust.
This ABC chapter was first published in the BMJ (2006;332:838-41).
studentBMJ 2006;14:441-484 December ISSN 0966-6494